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Fractional-dose	yellow	fever	vaccination:	an	antigen-sparing	strategy?		
Wilder-Smith A, Barrett ADT, Vannice K, Hombach J 	
In 2016, the World Health Organization (WHO) endorsed the use of fractional dose yellow 
fever (YF) vaccination subcutaneously in response to an acute vaccine shortage during a YF 
outbreak.1 The rationale for this recommendation was that standard doses of WHO-
prequalified (PQ) YF vaccines are highly potent, with average doses between 12,874 and 
43,651 international units (IU) — far above the WHO’s recommended minimum of 1000 IU. 
Some countries have considered the use of fractional-dose YF vaccination outside an 
emergency situation due to vaccine shortages.2 However, fractional YF vaccination is not yet 
compliant with the International Health Regulations (IHR). Critical research questions remain 
including the duration of immunity with a single dose of fractional YF vaccine, the 
immunogenicity of YF vaccine doses with potency below 1000 IU, and safety and 
immunogenicity across different populations. 
 
The study by Roukens et al in a recent issue of the Annals of Internal Medicine is therefore an 
important step forward in our understanding of the use of fractional YF vaccines.3 The 
authors studied the 10-year duration of immunogenicity of a 1/5th fractional dose given 
intradermally (ID). They showed that 40 healthy adults who had received a 0.1 ml fractional 
dose ID 10 years ago had similar virus-neutralizing antibody responses as 35 persons who had 
received the standard 0.5 ml dose SC also 10 years ago, with similar results to a recent study 
on 10 year duration of SC administration of a standard dose.4 While these results are 
encouraging and support the long-term immunogenicity of fractional doses as being similar to 
standard doses when administered by the ID route, important policy questions still remain. 
 
First, this study only investigated ID administration of fractional doses. However, YF vaccine 
is only licensed and WHO pre-qualified to be given by SC or intramuscular routes. Although 
the authors argue that viremia levels are equivalent when administered at the same dose by 
the ID and SC routes, immunogenicity typically differs with ID administration, and a head-to-
head comparison of ID versus SC routes on short-term and long-term immunogenicity will be 
needed to assess equivalence.  
  
Second, the potency of the fractional doses used in Roukens’ study was always above 1000 
IU and hence their study does not address the knowledge gap on long-term immunogenicity 
for doses that fall below the WHO minimum recommendation of 1000 IU. The primary study 
that informed the WHO recommendations to use fractional doses in 2016 was a dose–
response study investigating doses below 1000 IU, as low as 31 IU.5 In this dose de-
escalating study conducted in 2009 in Brazil with the Bio-Manguinhos YF vaccine, doses 
down to 587 IU showed similar humoral immunogenicity to the full dose (27,476 IU) both 
given subcutaneously, while the 158 IU and 31 IU doses displayed lower immunogenicity. A 
recall study of the same subjects undertaken 8 years later showed that seropositivity was 
maintained in 85% of the participants and was similar across the different potencies.6  
 
Third, Roukens` data are restricted to healthy adults and cannot necessarily be extrapolated to 
other populations. The extent and duration of protection of fractional doses in populations 
such as children, pregnant women, persons with HIV and other co-morbidities that may result 
in weakened vaccine responses are currently unknown. The first study on 1/5th dose including 
children down to two years of age was conducted in DRC after the emergency roll-out of 
fractional doses, and reassuringly showed high seroconversion one month following SC 
administration.7 The results of a randomized controlled non-inferiority trial comparing 
seroconversion after fractional-dose versus full-dose YF vaccination for each WHO-
prequalified vaccine product (ClinicalTrials.gov number, NCT02991495), including in 
special populations such as children and persons living with HIV, are now much awaited.  
 
Until those questions have been resolved for each WHO-PQ YF vaccine product, fractional 
YF vaccination is not yet IHR compliant and should only be used in emergency situations 
during acute vaccine shortage. Should SC fractional YF vaccination be shown to be 
equivalent to the standard dose, both in terms of long-term protection and safety, then the 
lower dose could become an antigen-sparing strategy of much broader utility.  
 
Disclaimer:  
AWS is consultant to WHO, JH is a WHO employee. The views expressed in this article are 
those of the authors and do not necessarily represent the decisions or policies of the World 
Health Organization. KV was on staff at the WHO during the development of its policy on 
fractional-dose vaccination.   
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